Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
EFPIA Japan Chief Frets Negative Market Growth amid Pressure on Drug Costs
Medium and long-term policies being weighed by the Japanese government to rein in drug spending would lead to negative growth in the country’s pharmaceutical market, EFPIA Japan Chairman Carsten Brunn warned on June 10. EFPIA Japan, formally the European Federation…
To read the full story
Related Article
- Japan Drug Costs to Remain Flat thru 2025, No Annual Price Cuts Necessary: EFPIA
April 15, 2015
- EFPIA Japan Chairman Says Drug Costs Won’t Explode
January 14, 2015
- EFPIA Japan Chairman Calls for More Rewards for Innovation
December 22, 2014
ORGANIZATION
- AMDD to Continue Policy Advocacy to Address Device Lag and Loss: Chair
January 28, 2026
- Off-Year Drug Price Revisions Run Counter to Innovation, JPMA Exec Says
January 23, 2026
- Kobe, iPark Institute, Partners Sign Pact to Accelerate Innovation at KBIC
January 21, 2026
- OTC Industry Head Urges Caution on Extra Charges for “OTC-Like” Drugs
January 20, 2026
- JETRO Picks 10 Overseas Startups for Regenerative Medicine Japan Entry Program
January 20, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…